Medesthetics

APR 2014

MedEsthetics—business education for medical practitioners—provides the latest noninvasive cosmetic procedures, treatment trends, product and equipment reviews, legal issues and medical aesthetics industry news.

Issue link: https://medesthetics.epubxp.com/i/283505

Contents of this Issue

Navigation

Page 38 of 78

34 APRIL 2014 | Med Esthetics By Linda W. Lewis Physicians compare the merits of Botox Cosmetic, Dysport and Xeomin, as a new wave of toxins vies for approval. IS THREE THE MAGIC NUMBER when it comes to neurotoxins? It has been three years since the FDA approved Xeomin (Merz Aesthetics, xeomin.com), the third injectable neurotoxin to enter the U.S. market— along with Botox Cosmetic (Allergan, botoxcosmetic.com) and Dysport (Medicis, dysportusa.com). In addition to a growing number of neurotoxin options, Botox Cosmetic recently received FDA approval for the treatment of crow's feet, and physicians are seeing continued growth in the numbers of women and men seeking these cosmetic treatments. The Power of © THINKSTOCK 3 P o w e r o f T h r e e / A d I n d e x M E D 4 1 4 . i n d d 3 4 Power of Three/Ad Index MED414.indd 34 3 / 1 8 / 1 4 1 2 : 4 1 P M 3/18/14 12:41 PM

Articles in this issue

Links on this page

Archives of this issue

view archives of Medesthetics - APR 2014